ClinConnect ClinConnect Logo
Search / Trial NCT05470907

Registry for Hemoperfusion of Covid-19 ICU Patients

Launched by CROATIAN SOCIETY FOR ORGAN SUPPORT · Jul 21, 2022

Trial Information

Current as of May 06, 2025

Completed

Keywords

Covid 19 Acute Respiratory Distress Syndrome Viral Disease Critical Illness Multi Organ Failure Systemic Inflammatory Response Syndrome Aki Acute Kidney Injury

ClinConnect Summary

The COVID-19 pandemic has been associated with high mortality rate and high percentage of patients with with severe multi-organ dysfunction. Many therapies were investigated in this group of patients. The usage of extracorporeal blood purification, namely hemoperfusion/hemadsorption was introduced in everyday clinical practice even before COVID-19 pandemic in which became increasingly common. The efficacy of hemoperfusion/hemadsorption in removal of endotoxins and cytokines is still questioned by some physicians mostly due to the fact that some trials failed to demonstrate the effect of thi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. COVID-19 infection
  • 2. laboratory and clinical evidence of systemic inflammation: high levels of inflammatory cytokines such as IL-6 (\>25 pg / ml); high values of inflammatory parameters from serum (leukocytes \>15x10 9 / l, CRP \>40 mg / l, procalcitonin \>0.9 mg / l) and a high SOFA score (\>2).
  • 3. diagnosed with sepsis or septic shock: sepsis is defined as the presence of suspected or documented infections along with systemic inflammatory response syndrome; septic shock is defined as the presence of sepsis and acute circulatory failure according to European criteria Society for Intensive Care Medicine
  • 4. clinical symptoms of hemodynamic instability requiring vasopressors and initial signs immune dysregulation or cascade coagulation disorders
  • 5. acute kidney injury assessed according to KDIGO / AKIN criteria: increase in serum creatinine ≥ 0.3 mg / dL within 48 hours, or ≥ 50% over 7 days, or hourly diuresis \<0.5 mL / kg / h for more than 6 hours
  • 6. diagnosis of ARDS
  • 7. the need for ECMO
  • 8. deterioration of respiratory status with the onset of respiratory failure requiring mechanical ventilation (respiration rate \>30 / min, or oxygen saturation \<93%, or PaO2 / FiO2 ratio \<300mmHg).
  • 9. Admission to ICU
  • Exclusion Criteria:
  • besides contraindications to the use of the hemoperfusion adopted (as from the manual of instructions), there are no exclusion criteria

About Croatian Society For Organ Support

The Croatian Society for Organ Support is a dedicated clinical trial sponsor focused on advancing research and development in the field of organ health and transplantation. Committed to improving patient outcomes, the Society collaborates with healthcare professionals, researchers, and institutions to facilitate innovative studies that enhance organ support therapies. With a strong emphasis on ethical practices and scientific rigor, the Croatian Society for Organ Support aims to contribute to the global body of knowledge in organ transplantation, ultimately striving to improve quality of life for patients in need.

Locations

Zagreb, Grad Zagreb, Croatia

Patients applied

0 patients applied

Trial Officials

Vedran Premuzic, M.D., Ph.D.

Principal Investigator

Clinical Hospital Centre Zagreb

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials